Compare Crispr Therapeutics AG (CRSP) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Crispr Therapeutics AG trades at $51.44 (market cap $4.88B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $25.55 (market cap $141.25M). The key difference: Crispr Therapeutics AG is far larger — about 34.5× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| CRSP | KOLD | |
|---|---|---|
Market Cap | $4.88B | $141.25M |
Volume | 2,861,747 | 5,492,367 |
Sector | Health | Leveraged / Inverse |
52-Week High | $74.92 | $49.39 |
52-Week Low | $44.34 | $13.58 |
Typical Hold Time | 77 Days | 10 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
KOLD is trading at $24.84, down 5.8% over the past 24 hours amid bearish technical signals. The stock faces significant selling pressure with moving averages indicating a strong downtrend, though oscillators remain neutral. Recent news highlights natural gas market volatility with record production levels and geopolitical tensions affecting energy sector sentiment. The stock currently trades near key support levels with resistance forming around $25-26.
The outlook remains challenging with bearish technical indicators and fundamental headwinds in the natural gas sector. Investment opportunities exist for contrarian investors betting on energy market recovery, but risks include continued production growth and weather-dependent demand. The stock's performance will likely track natural gas price movements and broader energy market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
